VIRGO

About the Study:

New Zealand Clinical Research is studying an experimental medication that may potentially be used for the treatment of autoimmune conditions, for example rheumatoid arthritis, in the future. Autoimmune conditions are common, with approximately 350 million people worldwide affected; approximately 1 in 50 New Zealander’s are affected.

It is called an experimental medication because it has not been approved by New Zealand’s MedSafe or other drug regulatory authorities.

Why Participate?

By participating in this study, you are contributing information that may be valuable in the advancement of medical science, which may support current and future patients.

•  Participation in this study will last up to approximately 18 weeks, including a screening, treatment, and follow-up period.
• The study requires a 2-night stay at the NZCR research unit followed by 11 scheduled clinic visits.
• If you wish to participate in this study, you will be booked for a consultation with a study doctor, and then asked to sign the consent form if you are still interested, before any study assessments can be performed.
• You will be reimbursed up to $4,500 NZD (before tax) for participating in this study.
• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time. Any information that you provide will be kept strictly confidential as required by law.
• You can be reassured that our experienced and qualified clinical staff will monitor your health throughout the study.

Study Visits: 2-night stay

Outpatient visits: 11 visits

Reimbursement: $4,500 (less tax)